PID23 injection for relapsed or refractory acute leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early phase 1 trial tests a new treatment called PID23 injection for patients whose acute leukemia has come back or has not responded to standard therapies. The goal is to see if PID23 is safe and effective in treating the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your legal guardian must agree to the study and sign a consent form.
- You must be between 3 and 75 years old.
- You must have acute leukemia that has come back after treatment or has not responded to standard chemotherapy.
- You should be well enough to perform daily activities (ECOG score 0-2) and have a life expectancy of at least 12 weeks.
- Your cancer cells must show a certain marker (CD19, BCMA, or CD70) and at least 5% blasts in bone marrow.
- Your heart, kidney, liver, lungs, and blood counts must meet minimum function levels.
- You cannot have had prior CAR-T therapy or certain other treatments recently.
- You cannot have severe heart problems, active infections, or uncontrolled graft-versus-host disease (GVHD).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a ready-made immune cell therapy (iNKT cells) that targets CD33 and CD70 proteins on leukemia cells. It is for people whose acute myeloid leukemia has come back or hasn't responded to treatment, offering a possible new option when standard therapies have stopped working.
This trial tests a new cell treatment called IBR733 for people with acute myeloid leukemia (AML) that has come back or not responded to other treatments. The goal is to see if it is safe and helps fight the leukemia.
This trial tests a new treatment using special immune cells that target a protein called CD33 on leukemia cells. It's for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) who still have small amounts of cancer cells left after other treatments.
This trial tests a new type of immune cell therapy (CAR-T) designed to find and kill leukemia cells that carry two specific markers (CLL-1 and CD33). It is for adults with acute myeloid leukemia that has come back or is not responding to standard treatments.
This trial tests an experimental drug, IDP-023, given alone or with antibody therapies for people with advanced blood cancers like multiple myeloma or non-Hodgkin lymphoma that have not responded to previous treatments. The goal is to see if it can shrink tumors or slow the disease.
This trial tests a new drug called PRG-2302 for people whose B-cell acute lymphoblastic leukemia (a type of blood cancer) has come back or not responded to standard treatments. The goal is to see if PRG-2302 is safe and can help control the disease.
Hear when a new Relapsed or Refractory Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.